A controlled clinical exploratory study on genetic markers for peri-implantitis.
The objective of this controlled exploratory cross-sectional study was to investigate and compare the presence of gene expression of bone resorption/remodelling in peri-implant crevicular fluid samples from healthy subjects and subjects showing obvious clinical and radiographic signs of peri-implantitis.
MATERIALS AND METHODS
Peri-implant crevicular fluid (PICF) was sampled from seven healthy subjects and seven subjects with obvious clinical signs of peri-implantitis using paper points. The samples were analysed by quantitative polymerase chain reaction (qPCR). Biomarkers associated with bone degradation/remodelling, such as tartrate-resistant acid phosphatase (TRAP), dickkopf-related protein- 1 (DKK-1), osteoprotegerin (OPG), cathepsin K (CatK) and osteocalcin (OC), were of particular interest in the study.
The measured levels of genetic markers were similar for the subjects in the healthy and the peri-implantitis group. Only one subject out of seven with strong and clear clinical signs of peri-implantitis exhibited a panel of genetic markers for ongoing bone degradation. This subject was also diagnosed with rheumatoid arthritis.
The present data showed that patients with obvious clinical signs of peri-implantitis and a history of bone loss can exhibit similar gene expressions of bone loss/remodelling as clinically healthy implant patients. Absence of bone resorption markers demonstrated that it was not possible to establish ongoing bone degradation in six of seven subjects in the peri-implantitis group. The results suggest that bone resorption was not in progress at the time of PICF sampling, or that cells expressing such markers were not present in significant numbers at the site of PICF sampling.
Nobel Biocare, Goteborg, Sweden. firstname.lastname@example.org
SourceEuropean journal of oral implantology 4:4 2011 pg 371-82
Gingival Crevicular Fluid
Intercellular Signaling Peptides and Proteins
Real-Time Polymerase Chain Reaction
Tumor Necrosis Factor-alpha
Pub Type(s)Clinical Trial
Research Support, Non-U.S. Gov't